Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

被引：0
|
作者：
Garcia, M. [1 ]
Schmid, S. [1 ]
Hueniken, K. [1 ]
Zhan, L. [1 ]
Balaratnam, K. [1 ]
Khan, K. [1 ]
Fares, A. [2 ]
Chan, S. [1 ]
Smith, E. [1 ]
Aggarwal, R. [1 ]
Brown, M. C. [1 ]
Patel, D. [1 ]
Sacher, A. [1 ]
Bradbury, P. [1 ]
Shepherd, F. A. [1 ]
Leighl, N. [1 ]
Liu, G. [1 ]
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Famerp, Ctr Oncol Hosp Base, Sao Jose Do Rio Preto, SP, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
NSCLC; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P48.05
引用
收藏
页码：S1107 / S1108
页数：2
相关论文
共 50 条
  • [11] The 5-years conditional disease free survival and overal survival for breast cancer patients in Korea
    Ahn, Jee Hyun
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeong Eon
    Chae, Byung-Joo
    Lee, Se Kyung
    Ryu, Jai Min
    Yu, Jonghan
    CANCER RESEARCH, 2020, 80 (04)
  • [12] Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib
    Lee, M.
    Miao, E.
    Zhang, C.
    Xue, X.
    Tuckman, S.
    Ohri, N.
    Halmos, B.
    Cheng, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S192 - S194
  • [13] Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
    Buder, A.
    Hochmair, M. J.
    Setinek, U.
    Filipits, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [14] High Expression of FGF5 Is an Independent Prognostic Factor for Poor Overall Survival and Relapse-Free Survival in Lung Adenocarcinoma
    Zhao, Teng
    Qian, Kun
    Zhang, Yi
    JOURNAL OF COMPUTATIONAL BIOLOGY, 2020, 27 (06) : 948 - 957
  • [15] Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
    Lee, Jiyun
    Choi, Yoon La
    Han, Joungho
    Park, Sehhoon
    Jung, Hyun Ae
    Su, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (11) : 1758 - 1766
  • [16] Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival
    Tefferi, Ayalew
    Barraco, Daniela
    Lasho, Terra L.
    Begna, Kebede H.
    Al-Kali, Aref
    Hogan, William J.
    Litzow, Mark R.
    Hanson, Curtis A.
    Ketterling, Rhett P.
    Gangat, Naseema
    Pardanani, Animesh
    BLOOD, 2016, 128 (22)
  • [17] Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
    Jimenez-Ubieto, Ana
    Grande, Carlos
    Caballero, Dolores
    Yanez, Lucrecia
    Novelli, Silvana
    Hernandez, Miguel T.
    Manzanares, Maria
    Arranz, Reyes
    Javier Ferreiro, Jose
    Bobillo, Sabela
    Mercadal, Santiago
    Galego, Andrea
    Lopez Jimenez, Javier
    Maria Moraleda, Jose
    Vallejo, Carlos
    Albo, Carmen
    Perez, Elena
    Marrero, Carmen
    Magnano, Laura
    Palomera, Luis
    Jarque, Isidro
    Coria, Erika
    Rodriguez, Antonia
    Martin, Alejandro
    Lopez-Guillermo, Armando
    Salar, Antonio
    Jose Lahuerta, Juan
    CANCER MEDICINE, 2017, 6 (12): : 2766 - 2774
  • [18] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
  • [19] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    De Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [20] The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression-free survival in patients with advanced EGFR-mutated NSCLC
    Han, Jie
    Xu, Yan
    Zhou, Yumei
    Yang, Aiju
    Cui, Jianfeng
    Chen, Pengxiang
    Zhao, Hongyu
    Zhou, Xingqin
    Shen, Chaoyan
    Yu, Jinming
    Lu, Heng
    ONCOLOGY LETTERS, 2020, 20 (01) : 391 - 400
12345